Cardiovascular disease and lung cancer.

conducted a large safety database review and found a highly significant increase in the incidence of myocarditis in combination nivolumab and ipilimumab therapy versus nivolumab monotherapy (0.27% vs. 0.06%; p<0.001; 5 fatal events vs. 1) ( 40 ).

also in 132,142 other papers